ArticleMolecular medicine reports2018
Effects of Shield1 on the viral replication of varicella‑zoster virus containing FKBP‑tagged ORF4 and 48.
Article in Molecular medicine reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 3 citations in OpenAlex.
- Point-of-Care Tests via Pollen-Based Nanoplasmonic Chips Combined with a Synthetic Receptor for FKBP12 Biomarker Detection at a Single-Molecule Level.ACS applied nano materials · 2025Article
- Identification and characterization of Varicella Zoster Virus circular RNA in lytic infection.Nature communications · 2024Article
- Mounting evidence of FKBP12 implication in neurodegeneration.Neural regeneration research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to explore the effects of a stabilizing ligand, Shield‑1, on the replication of recombinant varicella‑zoster virus (VZV) containing FK506 binding protein (FKPB) tags in essential open reading frames (ORF) 4 and 48. A specific galactokinase (galK) selection method was conducted, following the addition of galK labels to VZV ORF4 and 48, using a SW102 VZV bacterial artificial chromosome (BAC) system. Subsequently, recombinant VZV containing FKPB tags in ORF4 and 48 was constructed by counterselection and homologous recombination. Recombinant viral plasmids containing FKPB‑tagged VZV ORF4 and 48 were extracted and transfected into human acute retinal pigment epithelial ARPE‑19 cells. The results demonstrated that the FKPB‑tagged viral protein was rapidly degraded by proteases in recombinant virus‑infected ARPE‑19 cells. In addition, the recombinant VZVORF4‑FKBP‑ORF48‑FKBP virus could not grow if a synthetic ligand of FKBP, Shield1, was not added to the ARPE‑19 cell culture medium; however, the degradation of FKPB‑tagged viral protein was prevented if Shield1 was added to the ARPE‑19 cell culture medium, thereby allowing viral replication in ARPE‑19 cells. These results indicated that Shield1 may regulate replication of recombinant VZVORF4‑FKBP‑ORF48‑FKBP following transfection into human epithelial cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.